Welcome to The Aneurysm and AVM Foundation web site!

Dedicated to bettering the lives, support networks, and medical care of those affected by aneurysm and other types of vascular malformation of the brain.

Click Here to make a donation online to The Aneurysm and AVM Foundation to help further our efforts with research, education and support for brain aneurysms, arterviovenous and cavernous malformations

Annual Cerebrovascular Research Grant Awards

The Aneurysm and AVM Foundation seeks applications for scientific research projects that will significantly move the field forward toward effective understanding of the mechanisms of cerebrovascular disease. TAAF Grants respond to the cerebrovascular community's need for projects that highlight innovative research strategies that will support the development of novel cerebrovascular therapies, clinical management and recovery for patients.

Awards will be granted at a maximum of $25,000. Funds will not be granted for indirect costs. The award is open to all levels of investigators. Grant recipients will present their research at The Aneurysm and AVM Foundation's annual meeting or Awareness Walk event.

The application period for the 2017 grant season is now CLOSED!  All applications were due by April 3, 2017. If you need an extension, please email the address below no later than 04/05/17.  Applicants will be notified of the final decision by May 7, 2017. 

See application here.  Questions? Email us at research@taafonline.org

2016 Cerebrovascular Research Grants

The Aneurysm and AVM Foundation is pleased to announce the recipients of the 2016 Cerebrovascular Research Grant Awards. We selected three researchers (two grants) whose scientific projects showed the greatest potential to improve our understanding of cerebrovascular diseases.

Research Study:  An Investigation of Epoxyeicosatrienoic Acids as a Treatment Strategy to Improve Glymphatic Flow, Cerebral Blood Flow and Behavioral Outcomes Following Subarachnoid Hemorrhage in Rats

Primary Investigator:  Tristan Stani, MD, Dept. of Neurological Surgery at Oregon Health and Science University

Background: Aneurysmal subarachnoid hemorrhage (SAH) remains one of the most challenging stroke syndromes facing today's neurological critical care providers and surgeonsTristand Stani, MD.  Despite advances in characterizing the anatomical details of aneurysms and the continued development of novel surgical and endovascular techniques for securing aneurysms, the delayed consequences of initial aneurysm rupture continues to challenge care providers,  We continue to lack a sophisticated understanding of the exact systems that are disrupted following SAH and the mechanisms that underlie their dysfunction.  All too often the most technically successful treatment of a ruptured aneurysm is unfortunately marred by the delayed stroke and other cerebral dysfunction for which we have limited treatment options

Research Objective: The central objectives of this project are to determine the effectiveness of augmented levels of epoxyeicosatrienoic acids on rescuing perivascular flow of CSF through the glymphatic system in the setting of subarachnoid hemorrhage and to correlate post-SAH changes in the glymphatic system and subsequent glymphatic flow rescue by epoxyeicosatrienoic acids with post-SAH cerebral blood flow changes and behavioral outcomes. 

The “glymphatic system” is a cerebral microcirculation system of cerebral spinal fluid (CSF) that has only recently been described. Initial work on this system has suggested important connections with neurodegenerative diseases such as Alzheimer’s Disease. Importantly, the system has also recently been demonstrated to be disrupted following SAH and then restored after the delivery of tPA, a “clot-busting” drug commonly given in the clinical setting following acute ischemic stroke. This suggests important new treatment strategies for SAH.

Outcomes: With funding from The Aneurysm and AVM Foundation, Dr. Stani will launch a series of MRI imaging experiments which will characterize glymphatic CSF flow pre- and post-SAH.  He will then image glymphatic flow pre and post-SAH in an experimental group pretreated with analogs to epoxyeicosatrienoic acids (EETs).  EETs are endogenous molecules that the body already makes which possess profound anti-inflammatory, vasodilatory and fibrinolytic effects.  He hopes to demonstrate that the fibrinolytic  ("clot-busting") effects of EETs analogs will improve glymphatic CSF microcirculation and ultimately improve cerebral blood oxygen delivery and decrease cerebral inflammation following SAH, which will ultimately lead to improved outcomes.

Source: Tristan Stani, MD, Oregon Health and Science University. This research summary has been adapted and edited from Dr. Stani's research proposal.

 

Research Study:  Quality of Life in Patients Diagnosed with Unruptured Cerebral Aneurysm: Prospective Single-Center Series

Co-Primary Investigators:  Peter Gooderham, MD, Clinical Assistant Professor, Division of Neurosurgery, Dept. of Surgery at the University of British Columbia and Charlotte Dandurand, MD, Neurosurgery Resident at the University of British Columbia

Background: In the United States, 6 million people, 2% of the population, are living with an unruptured brain aneurysm.  Many of these people are unaware of their diagnosis.  The most important and devastating consequence of a brain aneurysm is subarachnoid hemorrhage from aneurysm rupture. Living with the diagnosis of an unruptured cerebral aneurysm can understandably cause anxiety for a patient and the impact on patients' quality of life is not well understood. The degree to which this diagnosis affects patients and how this affect changes over time remains unknown.  The impact of microsurgical clipping and endovascular coiling on patients' quality of life is also poorly studied

Research Objective: The objective of this research is to identify how the diagnosis of an unruptured cerebral aneurysm and its subsequent treatment impacts quality of life over time.

Outcomes: With funding from The Aneurysm and AVM Foundation, Dr.'s Gooderham and Dandurand will use objective quality of life tools to interview patients at diagnosis and again one year later.  Quality of life will be assessed at diagnosis, at 6-12 weeks post-operative follow-up, and at 1 year post-operative follow-up in patients who have been treated.  The latter group will be divided into 2 sub-groups, endovascular and microsurgical (clipping). Patient demographics, size and location of aneurysm, radiological features, presence and degree of neurological deficits, treatment modalities, and postoperative complications will also be collected.

Source: Charlotte Dandurand, MD, University of British Columbia. This research summary has been adapted and edited from Dr.'s Gooderham and Dandurand's research proposal.